MRDX Trademark

Trademark Overview

On Tuesday, January 26, 2016, a trademark application was filed for MRDX with the United States Patent and Trademark Office. The USPTO has given the MRDX trademark a serial number of 86886906. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, December 6, 2024. This trademark is owned by MolecularMD Corporation. The MRDX trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Medical testing for diagnostic or treatment purposes in the field of chronic myeloid leukemia
mrdx

General Information

Serial Number86886906
Word MarkMRDX
Filing DateTuesday, January 26, 2016
Status710 - CANCELLED - SECTION 8
Status DateFriday, December 6, 2024
Registration Number5475988
Registration DateTuesday, May 22, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 21, 2016

Trademark Statements

Goods and ServicesMedical testing for diagnostic or treatment purposes in the field of chronic myeloid leukemia

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, December 6, 2024
Primary Code044
First Use Anywhere DateMonday, August 1, 2016
First Use In Commerce DateSaturday, July 1, 2017

Trademark Owner History

Party NameMolecularMD Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressPortland, OR 97219
Party NameMolecularMD Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPortland, OR 97219
Party NameMolecularMD Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPortland, OR 97219

Trademark Events

Event DateEvent Description
Friday, January 29, 2016NEW APPLICATION ENTERED
Saturday, January 30, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 10, 2016ASSIGNED TO EXAMINER
Saturday, May 14, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 1, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 21, 2016PUBLISHED FOR OPPOSITION
Tuesday, June 21, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 16, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, January 13, 2017SOU TEAS EXTENSION RECEIVED
Friday, January 13, 2017SOU EXTENSION 1 FILED
Friday, January 13, 2017SOU EXTENSION 1 GRANTED
Tuesday, January 17, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 27, 2017TEAS STATEMENT OF USE RECEIVED
Thursday, July 27, 2017USE AMENDMENT FILED
Friday, August 18, 2017CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, August 19, 2017STATEMENT OF USE PROCESSING COMPLETE
Tuesday, September 12, 2017SU - NON-FINAL ACTION - WRITTEN
Tuesday, September 12, 2017NON-FINAL ACTION E-MAILED
Tuesday, September 12, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, March 12, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, March 22, 2018ASSIGNED TO LIE
Tuesday, March 27, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 27, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 19, 2018ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, April 20, 2018NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, May 22, 2018REGISTERED-PRINCIPAL REGISTER
Wednesday, July 14, 2021ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Monday, May 22, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, December 6, 2024CANCELLED SEC. 8 (6-YR)

Related Keywords

mrdx chronic myeloid leukemia field purposes testing diagnostic treatment medical